Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer

Published:2016-10-10 Issue:8 Volume:23 Page:1937-1944
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Ramalingam Suresh S.,Blais Normand,Mazieres Julien,Reck Martin,Jones C. Michael,Juhasz Erzsebet,Urban Laszlo,Orlov Sergey,Barlesi Fabrice,Kio Ebenezer,Keiholz Ulrich,Qin Qin,Qian Jiang,Nickner Caroline,Dziubinski Juliann,Xiong Hao,Ansell Peter,McKee Mark,Giranda Vincent,Gorbunova Vera

Funder

AbbVie Inc.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neurological toxicities with poly (ADP-ribose) polymerase inhibitors in cancer patients: a systematic review and meta-analysis;Journal of Chemotherapy;2024-08-23

2. Assessing the benefits and safety profile of incorporating poly ADP-ribose polymerase (PARP) inhibitors in the treatment of advanced lung cancer: a thorough systematic review and meta-analysis;Frontiers in Pharmacology;2024-06-21

3. Spatiotemporal Concurrent PARP Inhibitor Sensitization Based on Radiation‐Responsive Nanovesicles for Lung Cancer Chemoradiotherapy;Advanced Healthcare Materials;2024-04-21

4. Veliparib‑Induced Toxicity in Cancer Patients: A Systematic Review and Meta‑Analysis;Cancer Investigation;2024-03-15

5. Arterial hypertension associated with PARPi: A meta‐analysis of 41 placebo randomized controlled trials combined with a World Health Organization's pharmacovigilance study;Fundamental & Clinical Pharmacology;2024-01-25